PLG and Dravet syndrome: Recently, we reported that treatment with a synthetic plasmin inhibitor, YO-2, reduced γENaC activation and podocyte damage in DS rats, further underscoring the potential of targeting plasmin as a treatment way for salt-sensitive hypertension [15].